Page 186 - Haematologica-5

918
C. Perez-Sánchez et al.
tion of non-samll cell lung cancer. PLoS
One. 2012;7(2):e32307.
16. Sheinerman KS, Tsivinsky VG, Abdullah L,
Crawford F, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY). 2013;5(12):925- 938.
17. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012;18(17):4713- 4724.
18. Fortunato O, Boeri M, Verri C, et al. Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules. 2014;19(3):3038-3054.
19. Sharova E, Grassi A, Marcer A, et al. A circu- lating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362-1366.
20. Mayburd AL, Martlínez A, Sackett D, et al. Ingenuity network-assisted transcription profiling: Identification of a new pharmaco- logic mechanism for MK886. Clin Cancer Res. 2006;12(6):1820-1827.
21. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphos- pholipid syndrome: a pivotal role for mono- cyte tissue factor expression. Arthritis Rheum. 1997;40(5):834-841.
22. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease acti- vated receptors in monocytes from patients with primary Antiphospholipid syndrome. Arthritis Rheum. 2010; 62(3):869-877.
23. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expres- sion in monocytes from patients with pri- mary antiphospholipid syndrome. J Thromb Haemost. 2006;4(11):2461-2469.
24. Xiao B, Wang Y, Li W, et al. Plasma microRNA signature as a noninvasive bio- marker for acute graft-versus-host disease. Blood. 2013;122(19):3365-3375.
25. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood- based markers for cancer detection. Proc
Natl Acad Sci USA. 2008;105(30):10513-
10518.
26. Chen X, Ba Y, Ma L, et al. Characterization
of microRNAs in serum: a novel class of bio- markers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006.
MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. 2014; 18(12):1355-1365.
36. Li N, Wang K, Li PF. MicroRNA-34 Family and Its Role in Cardiovascular Disease. Crit Rev Eukaryot Gene Expr. 2015;25(4):293-
27. Dai Y, Huang YS, Tang M, et al. Microarray
analysis of microRNA expression in 297.
peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007;16: 939-946.
28. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for nor- mal immune function. Science. 2007;316(5824):608-611.
29. Wang J, Chen J, Sen S. MicroRNA as Biomarkers and Diagnostics. J Cell Physiol. 2016;231(1):25-30.
30. Nakamachi Y, Kawano S, Takenokuchi M. MicroRNA-124a is a key regulator of prolif- eration and monocyte chemoattractant pro- tein 1 secretion in fibroblast-like synovio- cytes from patients with rheumatoid arthri- tis. Arthritis Rheum. 2009;60(5):1294-1304.
31. Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid síndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood. 2012; 119(24):5859-5870.
32. Ruiz-Limón P, Barbarroja N, Pérez-Sánchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015;74(7):1450-1458.
37. Licholai S, Blaż M, Kapelak B, Sanak M. Unbiased Profile of MicroRNA Expression in Ascending Aortic Aneurysm Tissue Appoints Molecular Pathways Contributing to the Pathology. Ann Thorac Surg. 2016;102(4):1245-1252
33. Barbarroja N, Pérez-Sanchez C, Ruiz-Limon
P, et al. Anticyclic citrullinated protein anti-
bodies are implicated in the development of cardiovascular disease in rheumatoid arthri-
tis. Arterioscler Thromb Vasc Biol. 2014;34(12):2706-2716. 960.
34. Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as bio- markers of cardiovascular disease: a system- atic review. Cardiovasc Res. 2016;111(4):322-337.
35. Huang Y, Qi Y, Du JQ, Zhang DF.
44. Wu L, Zhou H, Lin H, et al. Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction. 2012;143(3):389-397.
45. Tatsumi K, Mackman N. Tissue Factor and Atherothrombosis. J Atheroscler Thromb. 2015;22(6):543-549
38. Choi SY, Yun J, Lee OJ, et al. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013;34(9):799-804.
39. Sheikh AM, Small HY, Currie G, Delles C. Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease. PLoS One. 2016;11(8): e0160808.
40. Akehurst C, Small HY, Sharafetdinova L, et al. Differential expression of microRNA-206 and its target genes in preeclampsia. J Hypertens. 2015;33(10):2068-2074.
41. Chan ES, Cronstein BN. Methotrexate--how does it really work? Nat Rev Rheumatol. 2010;6(3):175-178.
42. Tsochandaridis M, Nasca L, Toga C, Levy- Mozziconacci A. Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications. Biomed Res Int. 2015;2015:294954.
43. Zhao Z, Moley KH, and Gronowski AM. Diagnostic potential for miRNAs as bio- markers for pregnancy-specific diseases. Clinical Biochemistry. 2013;46(10-11):953-
haematologica | 2018; 103(5)